All Articles

Balancing cancer treatment with work responsibilities can be challenging for both employees and employers. But a program piloted at Johns Hopkins called Managing Cancer at Work (MCaW) provides people in the workplace with navigation assistance, thereby decreasing patients’ time away from work while increasing employee satisfaction and empowering employers, according to Lillie D. Shockney, RN, BS, MAS.

Dr Burhansstipanov emphasized the importance of coordination between NPNs and nurse navigators. “Our navigators have worked beautifully with nurse navigators,” she said at the Academy of Oncology Nurse & Patient Navigators 7th Annual Navigation & Survivorship Conference.

As the costs associated with cancer care continue to escalate, all key stakeholders—healthcare providers, private and government payers, and patients—strive to balance high-quality cancer care with cost efficiency.

Ms Shockney talks about the momentum of the navigation movement, accomplishments in 2016, and the expansion of JONS and AONN+ in 2017.

JONS talks to navigators Trish Leighton, Stephanie Hoopes, and Jo Weathers about their team-driven approach to patient care.

The authors present their findings from a patient satisfaction study conducted 1 year after the establishment of an oncology nurse navigation program to collect patient feedback and discover opportunities for improvements.

The authors present findings on the secondary aim of the Adherence, Communication, Treatment, and Support (ACTS) randomized controlled intervention study – a one-time psychoeducational intervention encouraging adherence of African American women to prescribed chemotherapy.

A report from the Association of Community Cancer Centers encouraging spiritual care plans for patients.

The addition of the selective CDK4/6 inhibitor ribociclib to letrozole significantly improved progression-free survival (PFS) in hormone receptor–positive (HR+) advanced breast cancer. Compared with letrozole alone, the combination of ribociclib/letrozole improved PFS by 44%.

Here is new information pertaining to this disease site for genetic testing and practice guidelines.